Free tool
FAERS Monitor: Exelderm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018737 or its brand name (Exelderm, Sulconazole Nitrate). Reports on generic versions are filed under their own applications.
Reports
23
Serious
13
57% of reports
Hospitalization
8
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3
- anxiety2
- erythema2
- fatigue2
- generalised pustular psoriasis2
- herpes zoster2
- hypotension2
- nausea2
- pruritus2
- abnormal dreams1
- acute kidney injury1
- altered state of consciousness1
- asthenia1
- atrial fibrillation1
- basal cell carcinoma1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| generalised pustular psoriasis | 2 | 6356.9 | 1682.4 | 7,099 |
| basal cell carcinoma | 1 | 58.6 | 8.6 | 14 |
| altered state of consciousness | 1 | 42.2 | 6.2 | 10 |
| abnormal dreams | 1 | 33.1 | 4.9 | 7 |
| herpes zoster | 2 | 31.8 | 8.5 | 33 |
| atrial fibrillation | 1 | 9.4 | 1.4 | 1 |
| hypotension | 2 | 9.1 | 2.4 | 8 |
| erythema | 2 | 8.9 | 2.4 | 7 |
| anxiety | 2 | 6.4 | 1.7 | 5 |
| acute kidney injury | 1 | 6.0 | 0.9 | 1 |
| pruritus | 2 | 4.8 | 1.3 | 3 |
| asthenia | 1 | 2.4 | 0.4 | 0 |
| fatigue | 2 | 2.3 | 0.6 | 1 |
| nausea | 2 | 2.3 | 0.6 | 0 |
| drug ineffective | 3 | 2.1 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.